Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

10374	Companies
216189	Keywords
145888	Articles
114464	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 02/18/2025 at 15:00, 1 year 2 months ago

Jaguar Health Extends Collaboration for Possible Tropical Disease Priority Review Voucher and Cholera Indication for NP-300
Jaguar Health and Napo Pharmaceuticals extend collaboration with Streeterville related to development of NP-300 drug product candidate for cholera patients, aiming for Tropical Disease Priority Review Voucher from FDA

Napo Pharmaceuticals Jaguar Health Cholera NP-300 Tropical Disease Priority Review Voucher
BRIEF

published on 02/13/2025 at 15:10, 1 year 2 months ago

Jaguar Health to Present at Emerging Growth Conference

Forward-looking Statements Jaguar Health Lisa Conte Emerging Growth Conference Gastrointestinal Medicines
BRIEF

published on 02/13/2025 at 15:10, 1 year 2 months ago

Jaguar Health participera à la conférence Emerging Growth

Lisa Conte Conférence Sur La Croissance Émergente Santé Jaguar Énoncés Prospectifs Médicaments Gastro-intestinaux
PRESS RELEASE

published on 02/13/2025 at 15:05, 1 year 2 months ago

Jaguar Health Presenting February 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. founder Lisa Conte to present virtually at Emerging Growth Conference on Feb 18, 2025. Company focuses on sustainable pharmaceuticals derived from rainforest plants for gastrointestinal distress

Pharmaceuticals Gastrointestinal Distress Jaguar Health Lisa Conte Emerging Growth Conference
BRIEF

published on 02/06/2025 at 16:05, 1 year 3 months ago

Magdalena Biosciences fera une présentation à la conférence des PDG et investisseurs de BIO

Santé Mentale Demande D'IND Biosciences De Magdalena Médicaments À Base De Plantes MB2500
BRIEF

published on 02/06/2025 at 16:05, 1 year 3 months ago

Magdalena Biosciences to Present at BIO CEO & Investor Conference

Mental Health Magdalena Biosciences IND Application Botanical Drugs MB2500
PRESS RELEASE

published on 02/06/2025 at 16:00, 1 year 3 months ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present February 10th at BIO CEO & Investor Conference
Magdalena to submit IND application for psychoactive drug candidate for mental health indications. MB2500 aims to treat cognitive deficit in schizophrenia and ADHD. Magdalena focuses on safe, plant-based drugs under FDA Botanical Guidance

Mental Health IND Application Magdalena Psychoactive Drug Cognitive Deficit
BRIEF

published on 02/03/2025 at 15:35, 1 year 3 months ago

Jaguar Health lance un essai pivot sur Crofelemer pour le SBS-IF et le MVID

Crofelemer Essais Cliniques MVID Médicaments Orphelins SBS-SI
BRIEF

published on 02/03/2025 at 15:35, 1 year 3 months ago

Jaguar Health Commences Pivotal Crofelemer Trial for SBS-IF and MVID

Crofelemer Clinical Trials Orphan Drugs MVID SBS-IF
PRESS RELEASE

published on 02/03/2025 at 15:30, 1 year 3 months ago

Jaguar Health Announces First Patient Dosed in Short Bowel Syndrome with Intestinal Failure in Investigator-Initiated Trial of Crofelemer; Proof-of-Concept Data Potentially Available H1 2025
Sheikh Khalifa Medical City hosts trial for Jaguar's crofelemer, plant-based drug granted Orphan Drug Designation. Study could lead to early patient access in Europe for rare diseases

Crofelemer Orphan Drug Designation SBS-IF Sheikh Khalifa Medical City Jaguar

Accesswire

Published on 05/09/2026 at 01:55, 2 days 4 hours ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 2 days 4 hours ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 2 days 4 hours ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 2 days 6 hours ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 2 days 7 hours ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 05/10/2026 at 16:05, 13 hours 59 minutes ago

RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
Published on 05/10/2026 at 14:00, 16 hours 4 minutes ago

MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Published on 05/10/2026 at 11:45, 18 hours 19 minutes ago

Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 1 day 10 hours ago

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 2 days 9 hours ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations

Les Echos

Published on 05/07/2026 at 19:15, 3 days 10 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 3 days 10 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 3 days 10 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 3 days 10 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 3 days 11 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE